Vyome Holdings, Inc. (HIND) is currently facing challenges in efficiently utilizing its capital. The company's Return on Invested Capital (ROIC) is a staggering -369.22%, which is far below its Weighted Average Cost of Capital (WACC) of 4.13%. This indicates that Vyome is not generating sufficient returns to cover its cost of capital, leading to a negative ROIC to WACC ratio of -89.29.
When comparing Vyome to its peers, Digital Brands Group, Inc. (DBGI) stands out with the least negative ROIC to WACC ratio of -1.65. Despite its ROIC of -63.30% and WACC of 38.33%, DBGI is relatively more efficient in capital utilization compared to Vyome. This suggests that while DBGI is still not meeting its cost of capital, it is closer to doing so than Vyome.
Palisade Bio, Inc. (PALI) also shows a negative ROIC of -309.15% against a WACC of 11.16%, resulting in a ROIC to WACC ratio of -27.70. This indicates that PALI, like Vyome, is struggling to generate returns that exceed its cost of capital, but it is slightly better off than Vyome in terms of capital efficiency.
Ensysce Biosciences, Inc. (ENSC) has an even more negative ROIC of -874.14% with a WACC of 41.64%, leading to a ROIC to WACC ratio of -20.99. This suggests that ENSC is facing significant challenges in capital utilization, even more so than Vyome, highlighting the difficulties within the industry.
Grom Social Enterprises, Inc. (GROM) and NeuroBo Pharmaceuticals, Inc. (NRBO) also exhibit negative ROICs of -59.49% and -269.72%, respectively. Their WACCs are 33.38% and 5.00%, resulting in ROIC to WACC ratios of -1.78 and -53.94. These figures further emphasize the widespread issue of negative returns across the peer group, indicating potential industry-wide challenges.
